CACI's Mission-Critical Technology will Accelerate the Delivery of Electronic Warfighting Capabilities to the U.S. Navy's Existing Fleet
"Today's threats are evolving at a rapid pace. Our innovative, software-defined solutions—which are open, modular, and scalable—empower our Navy to command dominance across every domain," said John Mengucci, CACI President and Chief Executive Officer. "With this latest award, we continue to iterate toward the next-gen future state, by accelerating the Navy's objective to rapidly and efficiently deploy mission-critical EW capabilities to sailors around the globe."
The $143 million firm-fixed-price delivery order represents a new phase of work on the CACI's existing Spectral contract with the Naval Information Warfare Systems Command (NAVWAR) which is authorized with a $1.2 billion ceiling value. The order demonstrates the Navy's solid commitment toward convergence of future capabilities and serves as a testimony to CACI's robust ability to deliver incremental, iterative functionality that can be rapidly deployed to keep our nation safe.
"These enabling kits will establish immediate capability to address current, new and emerging threats to the existing surface fleet in this highly complex and contested environment. They also make it increasingly clear that the Navy intends to fully realize the value and potential of its comprehensive, multi-domain Spectral mission and vision," Mengucci said.
About CACI
At CACI International Inc (NYSE: CACI), our 25,000 talented and dynamic employees are ever vigilant in delivering distinctive expertise and differentiated technology to meet our customers' greatest challenges in national security. We are a company of good character, relentless innovation, and long-standing excellence. Our culture drives our success and earns us recognition as a Fortune World's Most Admired Company. CACI is a member of the Fortune 1000 Largest Companies, the Russell 1000 Index, and the S&P MidCap 400 Index. For more information, visit us at www.caci.com.
There are statements made herein which do not address historical facts, and therefore could be interpreted to be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The factors that could cause actual results to differ materially from those anticipated include, but are not limited to, the risk factors set forth in CACI's Annual Report on Form 10-K for the fiscal year ended June 30, 2024, and other such filings that CACI makes with the Securities and Exchange Commission from time to time. Any forward-looking statements should not be unduly relied upon and only speak as of the date hereof.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Leonardo DRS, Mercury Systems, First Solar, Kimball Electronics, and BWX Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after investors took some profits off the table as markets awaited signals on future monetary policy from the Federal Reserve's Jackson Hole symposium later in the week. The downturn in the market was largely attributed to a significant sell-off in megacap tech and chipmaker shares. Nvidia, Advanced Micro Devices (AMD), and Broadcom all saw notable drops, dragging down the VanEck Semiconductor ETF. Other major tech-related companies like Tesla, Meta Platforms, and Netflix were also under pressure. A key reason for this trend is that much of the recent market gains have been concentrated in the "AI trade," which includes these large technology and semiconductor companies. So this could also mean that some investors are locking in some gains ahead of more definitive feedback from the Fed. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Defense Contractors company Leonardo DRS (NASDAQ:DRS) fell 3.7%. Is now the time to buy Leonardo DRS? Access our full analysis report here, it's free. Defense Contractors company Mercury Systems (NASDAQ:MRCY) fell 4.5%. Is now the time to buy Mercury Systems? Access our full analysis report here, it's free. Renewable Energy company First Solar (NASDAQ:FSLR) fell 4.9%. Is now the time to buy First Solar? Access our full analysis report here, it's free. Electrical Systems company Kimball Electronics (NASDAQ:KE) fell 3%. Is now the time to buy Kimball Electronics? Access our full analysis report here, it's free. Defense Contractors company BWX (NYSE:BWXT) fell 3.8%. Is now the time to buy BWX? Access our full analysis report here, it's free. Zooming In On First Solar (FSLR) First Solar's shares are extremely volatile and have had 36 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 1 day ago when the stock gained 10.4% on the news that the U.S. Treasury Department and IRS released new guidance on clean energy tax credits that was more favorable than investors had feared, continuing a rally from the previous session. This move extends a surge from the previous trading session as investors reacted positively to the updated rules, which were less restrictive than many had anticipated. The guidance clarifies how solar and wind projects can qualify for valuable federal tax credits. For large utility-scale projects, a focus for First Solar, the rules now emphasize a "physical work test" to determine if a project has begun, largely replacing a previous provision. This development has cleared up policy uncertainties that weighed on the solar sector for over a year. In response to the favorable guidance, analysts at UBS designated First Solar as a top pick, citing the reduced policy risk and potential for significant earnings growth. First Solar is up 12.9% since the beginning of the year, but at $210.57 per share, it is still trading 17.7% below its 52-week high of $255.75 from September 2024. Investors who bought $1,000 worth of First Solar's shares 5 years ago would now be looking at an investment worth $2,776. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Why Thermo Fisher Scientific Stock Was Topping the Market Today
Key Points The company has a new analyst tracking its fortunes. That pundit initiated coverage of the stock with the equivalent of a buy recommendation. 10 stocks we like better than Thermo Fisher Scientific › An analyst launched coverage of Thermo Fisher Scientific (NYSE: TMO) after market close on Monday, and the stock was experiencing a little pop the following day as a result. On Tuesday, it closed more than 2% higher in price, contrasting well with the 0.6% slide of the benchmark S&P 500 (SNPINDEX: ^GSPC). Buy, says a new bull Happily for investors, that pundit is bullish on Thermo Fisher's future. William Blair analyst Matt Larew ranked the healthcare device and services company's stock as an outperform (buy, in other words); it was unclear as of this writing if he set a price target. According to reports, Larew believes Thermo Fisher has numerous competitive advantages, and is leveraging them well. He wrote in his inaugural analyst note that the company offers best-in-class services, and with its range of products and services can act as something of a one-stop shop for customers. On a slightly negative note, Larew pointed out that the company's core biopharma client base is currently experiencing a degree of softness. However, he feels that with its extensive lineup of quality offerings, Thermo Fisher is well positioned to take advantage of that segment when it recovers. Oversold and undervalued Thermo Fisher's shares have been in something of a funk; in contrast to numerous other healthcare titles, they are down in price since the start of the year. Its recent fundamentals have been better than expected -- second-quarter revenue rose by almost 3% (to almost $10.9 billion), and non-GAAP (generally accepted accounting principles) adjusted EPS was at $5.36. Although both figures beat the consensus analyst estimates, they weren't crushing beats, and that top-line growth wasn't remarkable enough to move the stock. Do the experts think Thermo Fisher Scientific is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Thermo Fisher Scientific make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,076% vs. just 184% for the S&P — that is beating the market by 892.04%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Thermo Fisher Scientific. The Motley Fool has a disclosure policy. Why Thermo Fisher Scientific Stock Was Topping the Market Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Morgan Stanley Trims Coherent (COHR) Price Target, Cites 'Underwhelming' Outlook
Coherent Corp. (NYSE:COHR) is one of the On August 14, Morgan Stanley lowered the firm's price target on the stock to $89 from $97 and kept an Equal Weight rating on the shares. According to the analysts, Q4 EPS was better than Street estimates. However, Coherent's results and outlook were 'underwhelming.' This is particularly true considering how the stock jumped 20% the last month and elevated expectations based on other AI-related prints. Morgan Stanley believes that the stock is likely 'to remain in the penalty box for now.' A financial analyst intensely examining MSCI Korea 25/50 index and portfolio benchmarking. Coherent Corp. (NYSE:COHR) is an American manufacturer of optical materials and semiconductors. While we acknowledge the potential of COHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
